Benralizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Benralizumab and local guidelines before prescribing.
Anti-IL-5R monoclonal antibody
Mechanism
Anti-IL-5 receptor alpha monoclonal antibody.
Uses
Severe eosinophilic asthma, EGPA.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Headache, pharyngitis, hypersensitivity.
Interactions
Few.
Contraindications and cautions
Active parasitic infection
Monitoring
Asthma control
Pregnancy and breastfeeding
Limited data
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Depletes eosinophils; treat helminth infection first.
More from the textbook: uses, cautions and other points
- Benralizumab | IL-5 receptor (depletes eosinophils) | Severe eosinophilic asthma
Respiratory: Anatomy, Physiology and Pharmacology - Omalizumab / mepolizumab / benralizumab / dupilumab / tezepelumab | Biologics for severe asthma (specialist).
Respiratory: Anatomy, Physiology and Pharmacology - Severe eosinophilic asthma on maintenance prednisolone | Refer for biologic (e.g. mepolizumab, benralizumab)
Respiratory: Anatomy, Physiology and Pharmacology - Mepolizumab , reslizumab (anti-IL-5) and benralizumab (anti-IL-5 receptor): Severe eosinophilic asthma.
Respiratory: Airways Disease - Biologics (asthma) | Omalizumab (anti-IgE), mepolizumab, reslizumab, benralizumab (IL-5 pathway), dupilumab (IL-4/13), tezepelumab (TSLP) - specialist, NICE criteria.
Respiratory: Airways Disease - Cytokines - signalling proteins that coordinate immunity; many are now drug targets: Cytokine Main effects Blocked by TNF-α Inflammation, fever, cachexia, granuloma maintenance Infliximab, adalimumab, etanercept IL-1 Fever, inflammation - autoinflammatory diseases, gout Anakinra, canakinumab IL-6 Acute phase response (CRP), fever …
Clinical Immunology: Immune system basics and immunological investigations - IL-5 | Eosinophil production and survival | Mepolizumab, benralizumab (receptor)
Clinical Immunology: Immune system basics and immunological investigations - IL-5 / IL-5 receptor | Mepolizumab, reslizumab; benralizumab | Severe eosinophilic asthma, EGPA, hypereosinophilic syndrome | Parasitic infection (treat helminths first)
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (3 mentions)
- Respiratory: Airways Disease (2 mentions)
- Clinical Immunology: Immune system basics and immunological investigations (2 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated respiratory chapter (2 mentions)